ArticleNeurochemical research2011
Targeting of glycine site on NMDA receptor as a possible new strategy for autism treatment.
Article in Neurochemical research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- NMDA antagonist agents for the treatment of symptoms in autism spectrum disorder: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders.BMC psychiatry · 2013Trial
- Molecular Mechanisms of Aberrant Neuroplasticity in Autism Spectrum Disorders (Review).Sovremennye tekhnologii v meditsine · 2021Review
- Positive Modulation of SK Channel Impedes Neuron-Specific Cytoskeletal Organization and Maturation.Developmental neuroscience · 2020Article
- Fluoride Exposure Induces Inhibition of Sodium-and Potassium-Activated Adenosine Triphosphatase (NaInternational journal of environmental research and public health · 2019Review
- Comparative psychopharmacology of autism and psychotic-affective disorders suggests new targets for treatment.Evolution, medicine, and public health · 2019Review
- Impaired social behaviors and minimized oxytocin signaling of the adult mice deficient in the N-methyl-d-aspartate receptor GluN3A subunit.Experimental neurology · 2018Article
- Glutamate excitotoxicity induced by orally administered propionic acid, a short chain fatty acid can be ameliorated by bee pollen.Lipids in health and disease · 2017Article
- Glycine-dependent activation of NMDA receptors.The Journal of general physiology · 2015Article
- Increased glutamate and homocysteine and decreased glutamine levels in autism: a review and strategies for future studies of amino acids in autism.Disease markers · 2013Review
- N-acetylcysteine for treatment of autism, a case report.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2012Article
- Dog bites man or man bites dog? The enigma of the amino acid conjugations.Biochemical pharmacology · 2012Article
- Malondialdehyde, Bcl-2, superoxide dismutase and glutathione peroxidase may mediate the association of sonic hedgehog protein and oxidative stress in autism.Neurochemical research · 2012Review
- Targeting Mitochondria by Olesoxime or Complement 1q Binding Protein as a Novel Management for Autism: A Hypothesis.Molecular syndromology · 2011Article
- c-Kit+ cells transplantation as a new treatment for autism, a novel hypothesis with important research and clinical implication.Journal of autism and developmental disorders · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The exact pathophysiology of the neurodevelopment disorder of autism is not clear and there is not any curative approach for it. There is only one FDA-approved medication for its management. Therefore, providing of novel treatments is highly required. The hypofunction of GABAergic system and glutamate toxicity are generally believed to have a causal role for autism. The antagonist of the N-methyl-D-aspartic acid (NMDA) glutamate receptor improves autism. Glycine is required for the activation of NMDA receptor. The antagonist of glycine site decreases NMDA receptor conductance. It is hypothesis that glycine site antagonists can be tested as a new strategy for the management of autism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.